Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

CardioNet raises $110 mil. for wireless monitoring: Wireless outpatient cardiac arrhythmia monitoring product and service provider raises $110 million in a private placement, completed March 26. The funding follows San Diego-based CardioNet's acquisition of West Palm Beach-based heart monitoring service provider PDS Heart on March 12 for undisclosed terms. The purchase of PDS Heart makes CardioNet the largest U.S. provider of "wireless, remote outpatient cardiac monitoring, event Holter and pacer services," the firm says. Privately held CardioNet has raised nearly $200 million in private debt and equity over the past seven years. CardioNet gained 510(k) clearance in 2002 for its core technology for continuous outpatient monitoring to detect infrequent cardiac arrhythmias (1"The Gray Sheet" May 27, 2002, In Brief)...

You may also be interested in...



Edwards Set To Launch “Two-Trials-In-One” For Sapien Percutaneous Valve

Edwards Lifesciences will soon begin a 600-patient U.S. pivotal clinical trial for its Sapien transcatheter aortic replacement heart valve at Columbia University Medical Center and the Cleveland Clinic, the company says

CardioNet

The firm's first mobile outpatient cardiac telemetry service center will open for full commercial operation in Philadelphia in June. The facility will offer monitoring, reimbursement, physician in-service, sales and patient home hook-up services for Cardionet's ambulatory monitor, which was 510(k)-cleared in February for continuous outpatient monitoring to detect infrequent cardiac arrhythmias. The San Diego company sells the device and full monitoring service directly to cardiologists, focusing on electrophysiologists. Eventually, the company plans to have a service center in every major metropolitan area, but chose Philadelphia for its first center because of the relatively high Medicare reimbursement for "around-the-clock" cardiac telemetry that is available in Pennsylvania...

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

UsernamePublicRestriction

Register

MT024658

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel